When superstar cardiologist Dr. Sekar Kathiresan cataloged genes associated with coronary artery disease, he found nearly 60: some that decimate blood levels of LDL (“bad cholesterol”) and therefore protect against heart attacks, some that cause inflammation of arteries and so raise the risk of heart attacks, and scores more with effects on triglycerides, blood vessels, and other risk factors.

While existing drugs mostly operate far downstream of the genes, Kathiresan thought therapies operating at the level of DNA would let cardiologists “reimagine how we treat coronary artery disease, permanently protecting against it,” he said.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Congratulations to Sek K…for having tremendous vision and taking a bold steps to make it happen. Targeting elimination of atherosclerotic cardiovascular disease (heart and vascular) disease, the leading cause of death in the US, is a wonderful goal. Skeptics beware, Dr. Kathiresan is brilliant, strategic, and a force of nature. If anyone can drive this to successful outcome, it will be Sek. Best of luck and we are all rooting for you!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy